ReviewNature reviews. Disease primers2018
Melioidosis.
Review in Nature reviews. Disease primers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 428 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
428 citing papers in PubMed, 4 syntheses or guidelines pooled it, 638 citations in OpenAlex.
- Travel-Associated Melioidosis in Non-Endemic Regions: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2025Pooled it
- Whole Genome Sequencing and Comparative Genomics of the Emerging PathogenPathogens (Basel, Switzerland) · 2025Pooled it
- Neonatal patients with melioidosis: a systematic review.BMC infectious diseases · 2025Pooled it
- Diagnostic accuracy of non-culture methods for the diagnosis of melioidosis: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Rare bacterial infections and metagenomics: current diagnostic and therapeutic challenges-a literature review.Infection · 2026Review
- Timing of surgery for a melioidosis-associated abdominal aortic pseudoaneurysm: a case report.Tropical medicine and health · 2026Article
- Melioidosis in companion animals: Analysis of 45 Australian cases (24 dogs; 21 cats) from 1997 to 2025 and a brief review of the animal and human literature.Australian veterinary journal · 2026Review
- Development and evaluation of a multiplex PCR for simultaneous detection of Mycobacterium tuberculosis complex, Mycobacterium avium complex, and Burkholderia pseudomallei in clinical specimens.PLoS neglected tropical diseases · 2026Article
- Outcomes of patients with suspected or confirmed melioidosis: A prospective multinational, multicenter, observational study.PLoS neglected tropical diseases · 2026Observational
- Outer membrane engineering through lipid A modification allows modulation ofInfection and immunity · 2026Article
- Article
- Global research trends, knowledge structure, and future directions in melioidosis research: a bibliometric analysis, 1990-2025.Tropical medicine and health · 2026Article
- A prediction model for mortality risk in melioidosis patients based on clinical and laboratory indicators: A single-center retrospective study.PLoS neglected tropical diseases · 2026Article
- Development and international multicenter evaluation of a second-generation immunochromatography test for the serological diagnosis of melioidosis.PLoS neglected tropical diseases · 2026Article
- Melioidosis Seroprevalence in Animals: Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Mucosal-associated invariant T (MAIT) cells are reduced and dysfunctional in acute melioidosis.Scientific reports · 2026Article
- Hospital-Based Cross-Sectional Study ofGeoHealth · 2026Article
- Human infections caused by pathogenic Burkholderia: current clinical challenges and future perspectives.Infection · 2026Review
- Association of Diabetes Mellitus With a Shared Hyperinflammatory Immune Response in Patients With Melioidosis and Patients With Tuberculosis: An Observational Case-Control Study.Open forum infectious diseases · 2026Article
- Role of the Host Membrane Trafficking Protein Dynamin 2 in Cell-to-Cell Spread of Bacterial Pathogens.Cells · 2026Review
368 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 6 countries.
Funding
Abstract
Burkholderia pseudomallei is a Gram-negative environmental bacterium and the aetiological agent of melioidosis, a life-threatening infection that is estimated to account for ∼89,000 deaths per year worldwide. Diabetes mellitus is a major risk factor for melioidosis, and the global diabetes pandemic could increase the number of fatalities caused by melioidosis. Melioidosis is endemic across tropical areas, especially in southeast Asia and northern Australia. Disease manifestations can range from acute septicaemia to chronic infection, as the facultative intracellular lifestyle and virulence factors of B. pseudomallei promote survival and persistence of the pathogen within a broad range of cells, and the bacteria can manipulate the host's immune responses and signalling pathways to escape surveillance. The majority of patients present with sepsis, but specific clinical presentations and their severity vary depending on the route of bacterial entry (skin penetration, inhalation or ingestion), host immune function and bacterial strain and load. Diagnosis is based on clinical and epidemiological features as well as bacterial culture. Treatment requires long-term intravenous and oral antibiotic courses. Delays in treatment due to difficulties in clinical recognition and laboratory diagnosis often lead to poor outcomes and mortality can exceed 40% in some regions. Research into B. pseudomallei is increasing, owing to the biothreat potential of this pathogen and increasing awareness of the disease and its burden; however, better diagnostic tests are needed to improve early confirmation of diagnosis, which would enable better therapeutic efficacy and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.